Placeholder
Guardant Infinity™—
the ultimate power behind cancer testing.
The first and only commercially available technology that unlocks both
genomic and epigenomic insights for the most complete view of cancer.1
See more
with a multidimensional view

Unlock epigenomic biomarkers
for an additional layer of information.1

Genomic-only approaches offer an incomplete view of cancer.

All cells in the human body share one genome, yet certain cells behave
differently, showing that genomics is only one part of a much larger picture.2-5

Wheel graphic showcasing how Guardant Complete is showing a full view of cancer with epigenomics and multiomics. Wheel includes: deregulating cellular metabolism, resisting cell death, genome instability and mutation, inducing or accessing vasculature, activating invasion and metastases, tumor promoting inflammation, enabling replicative mortality, avoiding immune destruction, evading growth suppressors, and sustaining proliferative signaling.

While analyzing the genome can provide a foundational understanding of
cancer biology, a novel approach that goes beyond genomics is needed to
uncover potential insights that may guide future breakthroughs.6

Most precision oncology tests use technology
that only looks for genomic alterations.
Epigenomics is the missing link
in helping us better understand
what drives cancer behavior.4

Epigenomics examines chemical and structural modifications to DNA and
histones that affect gene expression and regulate biological processes—
without altering the underlying DNA sequence.7

Genomic alterations
Infographic with textbook visual of DNA displaying how multiomics maximizes sensitivity by including genomic alterations and epigenomic alterations, such as DNA methylation. Genomic alterations cover clonal driver alterations, including SNVs and Indels. Epigenomic alterations provides differential methylation in tumor DNA.

Genomic alterations change the underlying DNA.8

Epigenomic alterations
Infographic with textbook visual of DNA displaying how multiomics maximizes sensitivity by including genomic alterations and epigenomic alterations, such as DNA methylation. Genomic alterations cover clonal driver alterations, including SNVs and Indels. Epigenomic alterations provides differential methylation in tumor DNA.
Epigenomic alterations do not change the underlying
DNA sequence but can influence cancer behavior.3,7,8
DNA methylation is an epigenomic alteration
that can be an early driver of tumorigenesis by silencing
tumor suppressor genes or activating oncogenes.
Guardant Infinity
examines DNA methylation—
a powerful epigenomic biomarker.1,3

Compared with normal cells, cancer cells exhibit a distinct
methylation pattern.9

Guardant Infinity maps the unique epigenomic fingerprint of cancer
by examining differences in methylation patterns.1,4

Without lung cancer
With lung cancer
Constitutively methylated pattern unrelated to lung cancer.10
Infographic with textbook visual of DNA displaying constitutively methylated patterns unrelated to lung cancer. Constitutively methylated regions are segments of DNA with consistent methylation unrelation to cancer that serve as a control.

Constitutively methylated regions are segments of DNA with consistent
methylation unrelated to cancer that serve as a control.11

Analyzing abnormal methylation patterns can help detect cancer recurrence sooner and provide insights to improve therapy selection.
See more
with a multidimensional view

Unlock epigenomic biomarkers for an additional layer of information.1

Genomic-only approaches offer an incomplete view of cancer.

All cells in the human body share one genome, yet certain cells behave differently, showing that genomics is only one part of a much larger picture.2-5

Wheel graphic showcasing how Guardant Complete is showing a full view of cancer with epigenomics and multiomics. Wheel includes: deregulating cellular metabolism, resisting cell death, genome instability and mutation, inducing or accessing vasculature, activating invasion and metastases, tumor promoting inflammation, enabling replicative mortality, avoiding immune destruction, evading growth suppressors, and sustaining proliferative signaling.

While analyzing the genome can provide a foundational understanding of cancer biology, a novel approach that goes beyond genomics is needed to uncover potential insights that may guide future breakthroughs.6

Most precision oncology tests use technology that only looks for genomic alterations.
Epigenomics is the missing link in helping us better understand what drives cancer behavior.4

Epigenomics examines chemical and structural modifications to DNA and histones that affect gene expression and regulate biological processes—without altering the underlying DNA sequence.7

Genomic alterations
Infographic with textbook visual of DNA displaying how multiomics maximizes sensitivity by including genomic alterations and epigenomic alterations, such as DNA methylation. Genomic alterations cover clonal driver alterations, including SNVs and Indels. Epigenomic alterations provides differential methylation in tumor DNA.

Genomic alterations change
the underlying DNA.8

Epigenomic alterations

Infographic with textbook visual of DNA displaying how multiomics maximizes sensitivity by including genomic alterations and epigenomic alterations, such as DNA methylation. Genomic alterations cover clonal driver alterations, including SNVs and Indels. Epigenomic alterations provides differential methylation in tumor DNA.

Epigenomic alterations do not change the underlying DNA sequence but can influence cancer behavior.3,7,8

DNA methylation is an epigenomic alteration that can be an early driver of tumorigenesis by silencing tumor suppressor genes or activating oncogenes.
Guardant Infinity examines DNA methylation—a powerful epigenomic biomarker.1,3

Compared with normal cells, cancer cells exhibit a distinct methylation pattern.9

Guardant Infinity maps the unique epigenomic fingerprint of cancer by examining differences in methylation patterns.1,4
Without lung cancer
With lung cancer
Constitutively methylated pattern unrelated to lung cancer.10
Infographic with textbook visual of DNA displaying constitutively methylated patterns unrelated to lung cancer. Constitutively methylated regions are segments of DNA with consistent methylation unrelation to cancer that serve as a control.

Constitutively methylated regions are segments of DNA with consistent
methylation unrelated to cancer that serve as a control.11

Methylation pattern associated with lung cancer.10
Infographic with textbook visual of DNA displaying constitutively methylated patterns unrelated to lung cancer. Constitutively methylated regions are segments of DNA with consistent methylation unrelation to cancer that serve as a control.

Differentially methylated regions are segments of DNA unique to cancer used for ctDNA detection and clinical insights.12

Analyzing abnormal methylation patterns can help detect cancer recurrence sooner and provide insights to improve therapy selection.
Do more
with maximum performance

Analyze a larger set of signals to maximize sensitivity.1

With our proprietary technology, Guardant Infinity enables
100x—1000x more signals to be analyzed,
dramatically improving sensitivity compared to genomic-only profiling.13
Discover more
with continuous innovations

Leverage new test features and applications.1

Guardant Infinity is always evolving. Discover the latest features and applications.
Explore now
Look for tests powered by Guardant Infinity™.
Explore our tests
Explore the evidence backing Guardant tests and the Guardant Infinity technology.
See our evidence
ctDNA, circulating tumor DNA; mBC, metastatic breast cancer.

References: 1. Data on file. Guardant Health, Inc. Redwood City, CA. 2. National Human Genome Research Institute. A Brief Guide to Genomics. Published August 27, 2022. Accessed March 19, 2025. https://www.genome.gov/about-genomics/fact-sheets/A-Brief-Guide-to-Genomics 3. Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358(11):1148-1159. doi:10.1056/NEJMra072067. 4. LaFave LM, Savage RE, Buenrostro JD. Single-cell epigenomics reveals mechanisms of cancer progression. Annu Rev Cancer Biol. 2022;6:167-185. doi:10.1146/annurev-cancerbio-070620-094453. 5. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31-46. doi:10.1158/2159-8290.CD-21-1059 6. Angeles AK, Janke F, Bauer S, Christopoulos P, Riediger AL, Sültmann H. Liquid biopsies beyond mutation calling: genomic and epigenomic features of cell-free DNA in cancer. Cancers (Basel). 2021;13(22):5615. doi:10.3390/cancers13225615 7. Al Aboud NM, Tupper C, Jialal I. Genetics, Epigenetic Mechanism. In: StatPearls. Treasure Island (FL): StatPearls Publishing; August 14, 2023. 8. Chakravarthi BV, Nepal S, Varambally S. Genomic and epigenomic alterations in cancer. Am J Pathol. 2016;186(7):1724-1735. doi:10.1016/j.ajpath.2016.02.023 9. Liu P, Zhang J, Du D, et al. Altered DNA methylation pattern reveals epigenetic regulation of Hox genes in thoracic aortic dissection and serves as a biomarker in disease diagnosis. Clin Epigenetics. 2021;13(1):124. doi:10.1186/s13148-021-01110-9 10. Cho JW, Shim HS, Lee CY, et al. The importance of enhancer methylation for epigenetic regulation of tumorigenesis in squamous lung cancer. Exp Mol Med. 2022;54(1):12-22. doi:10.1038/s12276-021-00718-4 11. Gu J, Stevens M, Xing X, et al. Mapping of variable DNA methylation across multiple cell types defines a dynamic regulatory landscape of the human genome. G3 (Bethesda). 2016;6(4):973-986. doi:10.1534/g3.115.025437 12. Peters TJ, Buckley MJ, Chen Y, Smyth GK, Goodnow CC, Clark SJ. Calling differentially methylated regions from whole genome bisulphite sequencing with DMRcate. Nucleic Acids Res. 2021;49(19):e109. doi:10.1093/nar/gkab637 13. GuardantINFINITY™ Specification Sheet. Guardant Health, Inc. Redwood City, CA.